Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE015 (POL) (Dr. Ito)
· consented 2022-06-05
Adverse events
6
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-11-11 (study day 148); relationship: N
mild
assessed
2026-08-18
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-02-01 (study day 230); relationship: Y
moderate
assessed
2026-08-18
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-05-29 (study day 347); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2024-03-01 (study day 624); relationship: not assessed
severe
serious
assessed
2026-08-18
Grade 4 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2024-03-04 (study day 627); relationship: N; serious criteria: life-threatening
moderate
assessed
2026-08-18
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-03-27 (study day 650); relationship: N
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.